Tyra Biosciences/$TYRA
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Tyra Biosciences
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Ticker
$TYRA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
60
ISIN
US90240B1061
Website
Tyra Biosciences Metrics
BasicAdvanced
$578M
-
-$1.63
1.17
-
Price and volume
Market cap
$578M
Beta
1.17
52-week high
$27.66
52-week low
$6.42
Average daily volume
389K
Financial strength
Current ratio
22.783
Quick ratio
22.515
Long term debt to equity
1.761
Total debt to equity
1.892
Profitability
EBITDA (TTM)
-113.165
Management effectiveness
Return on assets (TTM)
-19.00%
Return on equity (TTM)
-27.04%
Valuation
Price to book
1.78
Price to tangible book (TTM)
1.78
Price to free cash flow (TTM)
-8.688
Free cash flow yield (TTM)
-11.51%
Free cash flow per share (TTM)
-125.00%
Growth
Earnings per share change (TTM)
-2.15%
3-year earnings per share growth (CAGR)
1.58%
What the Analysts think about Tyra Biosciences
Analyst ratings (Buy, Hold, Sell) for Tyra Biosciences stock.
Bulls say / Bears say
Analysts have consistently rated Tyra Biosciences as a 'Buy,' with an average price target of $30.83, indicating strong confidence in the company's growth potential. (Techdows News)
The company's innovative SNÅP precision medicine platform positions it at the forefront of developing therapies targeting oncology and genetically defined conditions, potentially leading to significant breakthroughs. (The AM Reporter)
Institutional investors, including Deutsche Bank AG, have increased their holdings in Tyra Biosciences, reflecting growing confidence in the company's future prospects. (ETF Daily News)
Tyra Biosciences reported a net loss of $28.15 million for the quarter ended March 31, 2025, highlighting ongoing financial challenges. (TradingView News)
The company's operating expenses increased to $31.85 million in Q1 2025, up from $22.32 million in the same quarter the previous year, indicating rising costs. (Tyra Biosciences, Inc.)
Despite positive analyst ratings, Tyra Biosciences' stock has experienced volatility, with shares losing 27.6% so far this year, raising concerns about market stability. (TradingView News)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Tyra Biosciences Financial Performance
Revenues and expenses
Tyra Biosciences Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tyra Biosciences stock?
Tyra Biosciences (TYRA) has a market cap of $578M as of July 18, 2025.
What is the P/E ratio for Tyra Biosciences stock?
The price to earnings (P/E) ratio for Tyra Biosciences (TYRA) stock is 0 as of July 18, 2025.
Does Tyra Biosciences stock pay dividends?
No, Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Tyra Biosciences dividend payment date?
Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Tyra Biosciences?
Tyra Biosciences (TYRA) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.